Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06623409 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Immunogenicity of V540B in Healthy Adults (V540B-002).

StatusRecruiting
PhasePhase 1
Started2024-11-12
View on ClinicalTrials.gov ↗
Researchers are looking for new ways to prevent cancers related to human papillomavirus (HPV). HPV is a common virus that can cause an infection. There are many different types of HPV. Most people's immune system can fight HPV infection and it goes away without treatment. For some people, HPV infections can last longer and may cause cancer years later. A standard vaccine to prevent HPV-related cancers is GARDASIL®9 (G9). G9 protects against 9 types of HPV but it does not protect against other types of HPV. The study vaccine (called V540B) is designed to protect against the same HPV types that G9 protects against plus other HPV types. The main goal of this study is to learn about the safety of V540B in healthy adults and if people tolerate it.

Amendment history 3 changes detected by DataLookout

2026-09-03
notable
Enrollment reopened
2026-09-02
critical
Primary completion pushed: 2026-11-20 → 2028-05-31
2026-09-02
minor
Completion pushed: 2026-11-20 → 2028-05-31
Trial Details
NCT Number NCT06623409
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Healthy
Enrollment 72 participants
Start Date 2024-11-12
Primary Completion 2028-05-31 (estimated)
Study Completion 2028-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-09-10